Introduction Epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed,
and mutated in multiple cancers. In normal cell physiology, EGFR signaling controls cellular …

Few data are available that have compared outcomes with different EGFR tyrosine kinase
inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell …

Over the past few decades, many of the phytochemicals have been shown to possess
extraordinary anticancer effects, clinical tested, approved as drugs, and currently in use. A …

Background Accumulating evidence has shown that dacomitinib has potential activities for
patients with non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth …

OBJECTIVES To clarify survival outcomes and prognostic factors of patients receiving
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) as first-line …

Background Dacomitinib is the second‐generation epidermal growth factor receptor (EGFR)‐
tyrosine kinase inhibitor (TKI) for mutant non–small cell lung cancer (NSCLC). EGFR‐TKIs …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been
established as the standard first-line treatment for patients with previously untreated …

Simple Summary The aim of this study was to evaluate treatment patterns and real-world
clinical outcomes since immunotherapy was introduced in Japan as the initial (first-line) …

Dacomitinib, the second-generation epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI), has been used as a first-line treatment in non-small cell lung cancer …

Introduction Osimertinib is the treatment of choice for epidermal growth factor receptor
(EGFR)-mutated advanced non–small-cell lung cancer (NSCLC). Because of its high price …